Understanding Antibody-Drug Conjugates (ADCs) in Metastatic Breast Cancer: Breakthroughs, Challenges, and the Future of Targeted Therapy

ADCs are a breakthrough in targeted chemotherapy for metastatic breast cancer. While ADCs like trastuzumab deruxtecan (T-DXd) offer new hope, challenges like resistance and various side effects still remain, and can therefore limit their clinical use.

In this episode, we sit down with Dr Michelle Li from the Peter MacCallum Cancer Centre to discuss:

• The current landscape of metastatic breast cancer.
• The role of ADCs in the treatment of metastatic breast cancer.
• What makes certain treatment options more effective than others in the context of metastatic disease?
• Future steps in this area of research, and the role of international collaboration.

Tune in for a deep dive into this important research.

⁠Donate to Support Life-Saving Research⁠ 

Like this episode? ⁠Find more Breast Cancer Trials Podcast Episodes here⁠

Follow Breast Cancer Trials on Social Media: 

• Instagram:⁠ @breastcancertrials⁠ 
• Facebook:⁠ Breast Cancer Trials⁠
• LinkedIn: ⁠Breast Cancer Trials⁠
• X: ⁠@BCTrialsANZ⁠

Guest: Dr Michelle Li, Medical Oncologist

Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of breast cancer clinical trials research.